Giant-Cell Arteritis Epidemiology

• Giant Cell Arteritis (GCA), or “Temporal Arteritis,” is an inflammation of the lining of the arteries (blood vessels). It most commonly affects the arteries in the head, particularly in the temporal region.
• As per Delveinsight, the total number of diagnosed prevalent cases of Giant Cell Arteritis in the US is ~270,000 in 2023.
• In 2023, the classic cranial GCA is more prevalent and accounted for the highest number of cases in the US i.e., 240,000 cases.
• Women are more likely to develop GCA than men. In the United States, the number of women cases of giant cell arteritis exceeds that of men by ~100,000.
• Giant cell arteritis is more common in the age group of 80-89 years and approximate 100,000 cases were related to this age group in US during year 2023. 

DelveInsight’s  “Giant Cell Arteritis – Epidemiology Forecast – 2034” report delivers an in-depth understanding of Giant Cell Arteritis, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The table given below further depicts the key segments provided in the report:

Giant Cell Arteritis: Disease Understanding 

Giant Cell Arteritis Overview, and Diagnosis

GCA is a systemic inflammatory vasculitis of unknown etiology that occurs in older persons and can result in a wide variety of systemic, neurologic, and ophthalmologic complications. GCA is one of the most common forms of systemic vasculitis in adults. GCA is classified as a large-vessel vasculitis but also involves medium and small arteritis, particularly the superficial temporal arteritis- hence it is termed temporal arteritis. Along with this, GCA most commonly affects the ophthalmic, occipital, vertebral, posterior ciliary, and proximal vertebral arteries. Medium- and large-sized vessels that may be involved include the aorta and the carotid, subclavian, and iliac arteries.

While a clinical presentation of headache, jaw claudication, scalp tenderness, fever, and other systemic symptoms and serum markers are together highly suggestive of the disease, diagnosis can be challenging in those cases in which classic symptoms are lacking. No test can confirm the presence of GCA. Primarily, the doctor will do a physical examination, and observe the symptoms and the medical history of the patient. Few tests including Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) blood tests, specialized ultrasound, and temporal artery biopsy etc. can be recommended by the physicians to confirm the presence of GCA in a patient.

The gold-standard test for GCA has traditionally been a temporal artery biopsy showing active inflammation of the temporal artery. If a doctor recommends a patient that they should have a temporal artery biopsy, this generally means they have a high level of suspicion for GCA.

Giant Cell Arteritis Epidemiology

The Giant Cell Arteritis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases Of Giant Cell Arteritis, Subtype- Specific Cases Of Giant Cell Arteritis, Gender Specific Cases of Giant Cell Arteritis, Age Specific Cases of Giant Cell Arteritis, Clinical Manifestation-Specific Cases of Giant Cell Arteritis, and Total Treated Cases Of Giant Cell Arteritis in the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2021 to 2034.

• In the 7MM, the total number of diagnosed prevalent cases of Giant Cell Arteritis were ~500,000 in 2023.
• Highest cases of Giant Cell Arteritis is related to classic cranial GCA and this trend is expected to persist in the forecast period. Overall classic cranial GCA cases contributed to approximately 52% of the total diagnosed prevalent cases in 2023 in the US.
• In 2023, the prevalent cases of scalp tenderness and Myalgia in the United States were 240,000 and 150,000 respectively.
• UK has the most prevalent cases of Giant Cell Arteritis among EU4 and UK, whereas the Spain has the fewest.
• The projected diagnosed prevalence growth rate of Giant Cell Arteritis is nearly 1.9%.

Scope of the Report

• The report covers a segment of key events, an executive summary, and a descriptive overview of Giant Cell Arteritis, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
• A detailed review of current challenges in establishing diagnosis and diagnosis rate is provided.

Giant Cell Arteritis Report Insights

• Patient Population
• Country-wise Epidemiology Distribution

Giant Cell Arteritis Report Key Strengths

• Eleven-year Forecast
• The 7MM Coverage 
• Giant Cell Arteritis Epidemiology Segmentation

Giant Cell Arteritis Report Assessment

• Epidemiology Segmentation
• Current Diagnostic Practices

FAQs

Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of Giant Cell Arteritis? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Giant Cell Arteritis?
• What is the historical and forecasted Giant Cell Arteritis patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What is the diagnostic pattern of Giant Cell Arteritis?
• Which clinical factors will affect Giant Cell Arteritis?
• Which factors will affect the increase in the diagnosis of Giant Cell Arteritis?
• Which subtype has a high patient share in the Giant Cell Arteritis?
• Which age group has a high patient share in the Giant Cell Arteritis?
• Which clinical manifestation has a high patient share in the Giant Cell Arteritis

Reasons to buy

• Insights on disease burden, details regarding diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the change in Giant Cell Arteritis cases in varying geographies over the coming years.
• A detailed overview of total diagnosed prevalent cases of giant cell Arteritis, subtype- specific cases of giant cell Arteritis, gender specific cases of giant cell Arteritis, age specific cases of giant cell Arteritis, clinical manifestation-specific cases of giant cell Arteritis, and total treated cases of giant cell Arteritis is included.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the treatment-eligible patient pool.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.